2 Oct 2026, 10:22
Presentations—
LTPLTR PHARMA LIMITED
Announcement history available from 1 August 2025
Fromto
1 Oct 2026, 08:24
Company UpdateMS
22 Sept 2026, 16:13
Meetings & Governance—
11 Sept 2026, 14:49
Securities Administration—
4 Sept 2026, 15:58
Securities Administration—
3 Sept 2026, 08:32
Presentations—
1 Sept 2026, 08:15
Company Update—
28 Aug 2026, 07:48
Financial ResultsMS
28 Aug 2026, 07:48
Company Administration—
28 Aug 2026, 07:48
Financial ResultsMS
11 Aug 2026, 08:32
Company UpdateMS
28 July 2026, 09:01
Quarterly ReportsMS
20 July 2026, 08:55
Company UpdateMS
17 July 2026, 08:48
Company UpdateMS
10 July 2026, 16:28
Securities Administration—
24 June 2026, 08:22
Company Update—
15 June 2026, 14:16
ASX QueryMS
11 June 2026, 08:38
Company UpdateMS
9 June 2026, 08:35
Company UpdateMS
1 May 2026, 09:19
PresentationsMS
1 May 2026, 09:18
Company UpdateMS
29 Apr 2026, 08:29
Trading Halt / SuspensionMS
28 Apr 2026, 08:52
Quarterly ReportsMS
11 Mar 2026, 08:40
Presentations—
5 Mar 2026, 08:31
Company UpdateMS
26 Feb 2026, 08:12
Financial ResultsMS
10 Feb 2026, 12:20
Securities Administration—
2 Feb 2026, 08:46
Company UpdateMS
28 Jan 2026, 08:27
Quarterly ReportsMS
22 Jan 2026, 08:52
Company UpdateMS
21 Jan 2026, 15:35
Securities Administration—
16 Jan 2026, 16:58
Securities Administration—
13 Jan 2026, 08:23
Company Update—
8 Jan 2026, 09:14
Company Update—
22 Dec 2025, 17:03
Securities Administration—
17 Dec 2025, 09:12
Company Update—
11 Dec 2025, 09:45
Securities Administration—
10 Dec 2025, 09:38
Company UpdateMS
3 Dec 2025, 09:19
Company UpdateMS
2 Dec 2025, 15:12
Securities Administration—
20 Nov 2025, 15:43
Director Interests—
20 Nov 2025, 15:40
Director Interests—
20 Nov 2025, 15:38
Director Interests—
20 Nov 2025, 10:13
Securities Administration—
20 Nov 2025, 10:06
Securities Administration—
20 Nov 2025, 09:59
Securities Administration—
19 Nov 2025, 08:32
Presentations—
30 Oct 2025, 09:43
Presentations—
29 Oct 2025, 08:51
Quarterly ReportsMS
24 Oct 2025, 16:32
Meetings & Governance—
| Date / Time | Heading | Type | MS | Report Codes | |
|---|---|---|---|---|---|
| 2 Oct 2026, 10:22 | Clinical and Commercial Update - Investor Webinar | Presentations | — | 14014 | |
| 1 Oct 2026, 08:24 | SPONTAN Phase II Final Results | Company Update | MS | 11001 | |
| 22 Sept 2026, 16:13 | Notice of Annual General Meeting/Proxy Form | Meetings & Governance | — | 08001, 08004 | |
| 11 Sept 2026, 14:49 | Application for quotation of securities - LTP | Securities Administration | — | 06020 | |
| 4 Sept 2026, 15:58 | Application for quotation of securities - LTP | Securities Administration | — | 06020 | |
| 3 Sept 2026, 08:32 | Investor Presentation | Presentations | — | 03026 | |
| 1 Sept 2026, 08:15 | LTR Expands Men's Health Portfolio with KYZATREX Pilot | Company Update | — | 11001 | |
| 28 Aug 2026, 07:48 | FY26 Results Announcement | Financial Results | MS | 03003 | |
| 28 Aug 2026, 07:48 | Appendix 4G and Corporate Governance Statement | Company Administration | — | 03024, 03025 | |
| 28 Aug 2026, 07:48 | Appendix 4E and Annual Report to Shareholders | Financial Results | MS | 03001, 03002, 03003, 03011, 03012, 03013, 03020 | |
| 11 Aug 2026, 08:32 | SPONTAN Real-World Study Reports 93% Response | Company Update | MS | 11001 | |
| 28 July 2026, 09:01 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19004, 19009 | |
| 20 July 2026, 08:55 | LTR Executes U.S. Commercial Agreement with Strive | Company Update | MS | 11001 | |
| 17 July 2026, 08:48 | LTR Executes Definitive U.S. Commercial Agreement with Shed | Company Update | MS | 11001 | |
| 10 July 2026, 16:28 | Notification regarding unquoted securities - LTP | Securities Administration | — | 06021 | |
| 24 June 2026, 08:22 | OROFLOW Clinical Study Receives Ethics Approval | Company Update | — | 11001 | |
| 15 June 2026, 14:16 | Response to ASX Aware Letter | ASX Query | MS | 17003 | |
| 11 June 2026, 08:38 | LTR Secures Exclusive U.S. Pharmacy Partner for ROXUS | Company Update | MS | 11001 | |
| 9 June 2026, 08:35 | LTR Secures First U.S. Commercial Agreement for ROXUS | Company Update | MS | 11001 | |
| 1 May 2026, 09:19 | Investor Presentation | Presentations | MS | 03026 | |
| 1 May 2026, 09:18 | SPONTAN Phase II data show rapid onset, support FDA pathway | Company Update | MS | 09014, 11001 | |
| 29 Apr 2026, 08:29 | Trading Halt | Trading Halt / Suspension | MS | 09007 | |
| 28 Apr 2026, 08:52 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19003, 19008 | |
| 11 Mar 2026, 08:40 | Investor Presentation | Presentations | — | 03026 | |
| 5 Mar 2026, 08:31 | SPONTAN Phase II Clinical Study Completes Recruitment | Company Update | MS | 11001 | |
| 26 Feb 2026, 08:12 | Appendix 4D and Half Yearly Report | Financial Results | MS | 03004, 03009, 03010, 03015, 03019 | |
| 10 Feb 2026, 12:20 | Application for quotation of securities - LTP | Securities Administration | — | 06020 | |
| 2 Feb 2026, 08:46 | SPONTAN Shows Positive Outcomes in Younger Men with ED | Company Update | MS | 11001 | |
| 28 Jan 2026, 08:27 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19002, 19007 | |
| 22 Jan 2026, 08:52 | First Patients Dosed in SPONTAN Phase II Clinical Study | Company Update | MS | 11001 | |
| 21 Jan 2026, 15:35 | Application for quotation of securities - LTP | Securities Administration | — | 06020 | |
| 16 Jan 2026, 16:58 | Notification regarding unquoted securities - LTP | Securities Administration | — | 06021 | |
| 13 Jan 2026, 08:23 | Patient Recruitment Commences for SPONTAN Phase II Study | Company Update | — | 11001 | |
| 8 Jan 2026, 09:14 | SPONTAN Phase 1 Study Accepted for WMSM 2026 Podium | Company Update | — | 11001 | |
| 22 Dec 2025, 17:03 | Notification regarding unquoted securities - LTP | Securities Administration | — | 06021 | |
| 17 Dec 2025, 09:12 | LTR Pharma Surpasses 1,000 SPONTAN Prescriptions | Company Update | — | 11001 | |
| 11 Dec 2025, 09:45 | Application for quotation of securities - LTP | Securities Administration | — | 06020 | |
| 10 Dec 2025, 09:38 | TGA Provides Regulatory Clearance for SPONTAN Phase II | Company Update | MS | 11001 | |
| 3 Dec 2025, 09:19 | Ethics Approval Received for SPONTAN Phase II Clinical Study | Company Update | MS | 11001 | |
| 2 Dec 2025, 15:12 | Release of Restricted Securities from ASX Mandatory Escrow | Securities Administration | — | 06009 | |
| 20 Nov 2025, 15:43 | Change of Director's Interest Notice - M McGuire | Director Interests | — | 02009 | |
| 20 Nov 2025, 15:40 | Change of Director's Interest Notice - J Chick | Director Interests | — | 02009 | |
| 20 Nov 2025, 15:38 | Change of Director's Interest Notice - L Rodne | Director Interests | — | 02009 | |
| 20 Nov 2025, 10:13 | Notification regarding unquoted securities - LTP | Securities Administration | — | 06021 | |
| 20 Nov 2025, 10:06 | Notification regarding unquoted securities - LTP | Securities Administration | — | 06021 | |
| 20 Nov 2025, 09:59 | Application for quotation of securities - LTP | Securities Administration | — | 06020 | |
| 19 Nov 2025, 08:32 | Bell Potter Healthcare conference presentation | Presentations | — | 03026 | |
| 30 Oct 2025, 09:43 | Investor Presentation | Presentations | — | 03026 | |
| 29 Oct 2025, 08:51 | Quarterly Activities/Appendix 4C Cash Flow Report | Quarterly Reports | MS | 19001, 19006 | |
| 24 Oct 2025, 16:32 | Results of Meeting | Meetings & Governance | — | 08003 |
1–50 of 63
1 / 2